



ASX ANNOUNCEMENT

IMPEDIMED STRENGTHENS BOARD WITH U.S. APPOINTMENT

15 May 2013

Brisbane, Australia – Consistent with assurances given at its 2012 AGM, **ImpediMed Limited** (ASX: IPD) (“ImpediMed”) announces the first step in the implementation of its plan to refresh the board through a carefully considered process of retirement, and appointment of U.S. based Directors. Director Martin Kriewaldt will retire from the Board effective July 2013 to be replaced by Scott R Ward, a seasoned US Director with over 30 years of experience in the medical device industry. As a further step in this process, founder and long term chairman Mel Bridges will retire from the board at the 2013 AGM and will be replaced by a second U.S. based Director.

Martin Kriewaldt joined the ImpediMed board in 2005. His contribution to the company throughout the intervening eight years has been outstanding, delivered through his extensive legal and business knowledge and experience. “I wish to thank Martin for his long-term dedication and commitment to ImpediMed. His work over the years has seen ImpediMed through many phases of development” ImpediMed Chairman Dr. Cherrell Hirst said. His very significant expertise will be missed but his position will be ably taken by Scott Ward.

Scott R. Ward will be appointed to the ImpediMed Board on Mr. Kriewaldt’s retirement in July. “ImpediMed is extremely fortunate to be gaining as a director someone of Mr. Ward’s standing and experience in the medical device world” said Dr. Hirst.

Mr. Ward has a long and distinguished career in the medical devices industry. He was formerly an Officer at Medtronic and the Senior Vice President and President of Medtronic CardioVascular. In this role, he was responsible for the worldwide operations of the Coronary, Peripheral, Endovascular and Structural Heart Disease business units. He currently serves on multiple other Boards, including SurModics, Inc, Creganna-Tactx Medical and Gillette Children’s Specialty Healthcare.

“Mr. Ward’s strong operational experience, along with his deep understanding of all aspects of a medical device company development, will contribute greatly to our growth plans and outreach efforts in the coming months and years,” said Dr. Hirst. “This is part of our strategic focus and strengthens our future in the US market place,” added Dr. Hirst. “Scott’s extensive understanding of regulatory affairs, clinical research and business development in the U.S. medical device setting arena will give additional support to our operations” added ImpediMed’s CEO Richard Carreon.

For further information contact:

Richard Carreon, ImpediMed CEO
T: +1 (858) 412-0200

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For personal use only

